Search the Newsreel

Nektar Therapeutics (NKTR) Stock Looks Stretched Despite New Phase 3 Trial Launch

Vera Therapeutics (NASDAQ:VERA) Shares Gap Up - Here's Why

Notable ETF Outflow Detected - SPSM, CORT, GKOS, EAT

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR Portfolio S&P 600 Small Cap ETF (Symbol: SPSM) where we have detected an approximate $125.1 million dollar outflow -- that's a 0.7% decrease …

JSPR Financials: Income Statement, Balance Sheet & Cash Flow | Jasper Therapeutics Inc

Nektar Q2 Earnings Beat Estimates, Revenues Lag, Pipeline in Focus

Nektar Therapeutics NKTR reported a loss of $1.23 per share for the second quarter of 2026, much narrower than the Zacks Consensus Estimate of a loss of $2.06. In the year-ago quarter, the company had incurred a loss of $2.95 cents per share. Total …

Tapestry's Coach International Growth Could Offset North America Slowdown, Morgan Stanley Says

Tapestry's (TPR) fiscal Q4 results showed a slowdown in Coach's North American business, but stronger international growth could support the company's growth trajectory, Morgan Stanley said.Coach North America growth slowed to 10% year over year in Q4, while international sales Silver Upgrade to read …

Quince Therapeutics Q2 EPS of $(12.31) beats $(26.32) estimate

Quince Therapeutics (NASDAQ: QNCX) significantly beat Q2 2026 EPS estimates with a loss of $(12.31) against a consensus of $(26.32), marking an 81.9% improvement year-over-year. The company completed its acquisition of Orphai Therapeutics and raised $115 million in a private placement, strengthening its cash …

Woodline Partners discloses 4.8M-share Zevra Therapeutics (ZVRA) ownership position

Woodline Partners LP has reported an 8.1% beneficial ownership stake in Zevra Therapeutics, Inc. (ZVRA), amounting to 4,785,771 shares. This disclosure, made via an amended Schedule 13G, indicates that Woodline Partners has sole voting and dispositive power over these shares. The ownership percentage is …

Bernstein raises Tapestry stock price target to $185 on Coach growth

Bernstein SocGen Group has increased its price target for Tapestry Inc. (NYSE:TPR) to $185, citing the strong growth of its Coach brand. This adjustment comes amidst Tapestry's impressive financial performance, including 14% revenue growth and a 78% gross profit margin, with analysts noting the …

Candel Therapeutics (NASDAQ:CADL) Stock Price Down 4.6% After Earnings Miss

Candel Therapeutics (NASDAQ:CADL) stock fell 4.6% after reporting a quarterly loss of $0.52 per share, missing the consensus estimate of $0.27. Despite the earnings miss, management highlighted progress towards a biologics license application submission in Q4 and a first commercial product target for 2027. …

Armistice Capital (VYGR) files 13G/A showing 3.44M Voyager Therapeutics shares

Armistice Capital, LLC and Steven Boyd have filed a Schedule 13G/A, reporting a beneficial ownership of 3,436,000 shares of Voyager Therapeutics, Inc. (VYGR) common stock, which represents 5.58% of the class. They hold shared voting and dispositive power over these shares, which are directly …

Armistice Capital discloses 4.99% VVOS position in Vivos Therapeutics (VVOS)

Vivos Therapeutics schedules Q2 2026 results, conference call

Vivos Therapeutics Inc (NASDAQ: VVOS) is set to release its second quarter 2026 financial results after market close on August 14, 2026. Following the release, the company will host a conference call at 5:00 pm ET to discuss the results, provide operational updates, and …

Why Medicenna Therapeutics Corp stock is skyrocketing today

OCUL|Ocular Therapeutix Inc|Price:9.890|Chg%:-0.210

This article provides detailed financial and analytical data for Ocular Therapeutix Inc (OCUL), including its live stock price, chart, news, and a comprehensive stock score. It covers key financial figures, performance over various periods, technical analysis, analyst ratings, and company profile. The data shows …

Galectin Therapeutics Q2 Results: EPS misses estimate, losses widen

Candel Therapeutics, Inc. Stock 12‑Month Price Target Raised to $20.88, Implies 77% Upside

Candel Therapeutics, Inc. (CADL) has seen its average 12-month price target raised to $20.88 by analysts, up from $20.5, with individual forecasts ranging from $12 to $29. This new target suggests a potential upside of approximately 77% from its closing price on August 13. …

Tapestry (TPR) Is Down 20.7% After Soft 2027 Outlook Tempers Dividend Hike And Buybacks

Tapestry, Inc. has already reported fourth-quarter and full-year 2026 results, with sales rising to US$1,876.6 million and US$8,004.2 million respectively, alongside a swing from loss to profit and a Board-approved 16% increase in the quarterly dividend to US$0.4625 per share. The company also completed …

T. Rowe Price Associates (CLDX) discloses 6.0% Celldex Therapeutics ownership on Schedule 13G

T. Rowe Price Associates has disclosed a 6.0% beneficial ownership stake in Celldex Therapeutics Inc. (CLDX) through a Schedule 13G filing. The firm reported holding 4,686,187 shares of common stock, with sole voting power over 4,683,226 shares and sole dispositive power over all 4,686,187 …

Galectin Therapeutics Releases Q2 2026 Financial Results

Galectin Therapeutics Inc. (GALT) reported a wider net loss of $0.14 per share, or $9.1 million, for Q2 2026, an increase from $0.12 per share in the prior year. This reflects the company's continued investment in developing new drugs for fibrotic disease and cancer …

T. Rowe Price Associates (RNA) discloses 8.6% Atrium Therapeutics ownership in 13G/A

T. Rowe Price Associates, Inc. has filed an amended Schedule 13G, disclosing a beneficial ownership of 1,472,984 shares in Atrium Therapeutics Inc., which constitutes an 8.6% stake in the company. The filing indicates that T. Rowe Price Associates holds sole voting power over 1,472,772 …

Eikon Therapeutics, Inc. Stock 12‑Month Price Target Cut to $24.6, Implies 138% Upside

Eikon Therapeutics, Inc.'s average 12-month price target has been lowered to $24.6 from $24.8 by 5 analysts, with individual forecasts ranging from $4 to $32 per share. This new target suggests a potential upside of approximately 138% based on the August 13 closing price. …

Armistice Capital (BCYC) reports 3.40M Bicycle Therapeutics ADSs in 13G/A

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting beneficial ownership of 3,398,000 American Depositary Shares (ADSs) of Bicycle Therapeutics plc (BCYC). This represents 6.72% of the outstanding class as of June 30, 2026. All voting and dispositive power over …

DFTX News Today | Why did Definium Therapeutics stock go down today?

TPR Q4 Earnings Call Puts Coach Growth Durability in Focus

Tapestry, Inc. TPR used its fiscal fourth-quarter call to emphasize that Coach can sustain growth in fiscal 2027 despite a more measured second-half cadence. TPR reported adjusted earnings of $1.32 per share, which beat the Zacks Consensus Estimate of $1.26. Revenues of $1,876.6 million …

HC Wainwright Issues Negative Forecast for TARA Earnings

United Therapeutics’s Q2 Earnings Call: Our Top 5 Analyst Questions

United Therapeutics's Q2 Earnings Call: Our Top 5 Analyst Questions United Therapeutics reported second quarter results that modestly exceeded Wall Street's revenue and adjusted EPS expectations, with management highlighting the impact of competitive dynamics in the inhaled prostacyclin market. CEO Dr. Martine Rothblatt emphasized …

Protara Therapeutics, Inc. Actuals & Estimates (NASDAQ:TARA)

HC Wainwright Has Positive Estimate for VERA Q3 Earnings

Allogene Therapeutics (ALLO) Income Statement & Earnings

Chenming Paper Faces RMB792.9 Million in New Litigation Amid Stable Operations

Filana Therapeutics, Inc.: Revenue and Earnings Analysts Forecasts Revisions | PX91 | US14817C1071

Werewolf Therapeutics Company Profile & Introduction

Wedbush Reaffirms "Outperform" Rating for Fate Therapeutics (NASDAQ:FATE)

Wedbush has reaffirmed an "Outperform" rating for Fate Therapeutics (NASDAQ:FATE), setting a target price of $7.00, which suggests a significant upside of approximately 178% from its current share price. The biopharmaceutical company recently surpassed quarterly expectations, reporting a smaller-than-anticipated loss of $0.25 per share …

Autolus Therapeutics (AUTL): Armistice Capital discloses 15M-share, 5.64% ADS stake

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 15,000,000 American Depositary Shares (ADSs) in Autolus Therapeutics plc (AUTL), representing 5.64% of the outstanding ADSs. The shares are held by Armistice Capital Master Fund Ltd., with Armistice Capital serving as the …

Armistice Capital (BTAI) discloses 4.99% BioXcel Therapeutics stake via managed fund

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 4.99% in BioXcel Therapeutics, Inc. (BTAI), amounting to 1,621,716 shares. These shares are held through Armistice Capital Master Fund Ltd., with Armistice Capital exercising shared voting and dispositive power as the investment …